Uriach sells its pharmaceutical business to the MCH fund and will focus on personal care. It expects to bill between 450 and 500 million in 2025 with purchases in Europe.
Uriach has agreed to sell its pharmaceutical business to the MCH fund and will focus on the personal self-care division (Consumer Healthcare), which was the fastest growing division in recent years and which plans to double in size until 2025, reaching between 450 and 500 million euros. euros of turnover through acquisitions and organic advance.
The pharmaceutical business, which accounts for around a third of Uriach and its historical base and whose formalization of the sale is expected before the end of the year, includes molecules, generics and manufacturing for third parties, with two production plants in Catalonia and one expected turnover of 80 million euros this year.
The CEO of Uriach, Oriol Segarra, explained at a press conference that the sale agreement includes maintaining the staff of the split division (about 400 people) and working conditions, and has defended that this decision was “the best solution “to promote the growth of both businesses.
He added that it represents the culmination of a transformation carried out in the last decade in the Catalan company, driven by the fifth generation of the owner family, to gain size, profitability, professionalization, internationalization and a focus on natural, scientific-based personal care products. , such as Biodramina, Aerored and Aquilea.